🇺🇸 FDA
Patent

US 11116823

Treatment of α-galactosidase a deficiency

granted A61KA61K38/00A61K38/47

Quick answer

US patent 11116823 (Treatment of α-galactosidase a deficiency) held by Takeda Pharmaceutical Company Limited expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K38/00, A61K38/47, A61P, A61P13/12